Business Context and Reporting Period
Company: Arrowhead Research Corporation (formerly InterActiveGroup, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2005
Business Model: A development-stage nanotechnology company operating through three strategic components: an Outsourced R&D Program (funding university/government research), a Commercialization Program (majority-owned subsidiaries), and a Patent Toolbox. The company has no product sales revenue to date; revenue is derived from grants and licensing fees.
Key Financial Metrics
| Metric | Q4 2005 | Q4 2004 |
|---|---|---|
| Revenue | $252,500 | $129,490 |
| Operating Expenses | $4,305,232 | $1,797,196 |
| Operating Loss | $(4,052,732) | $(1,677,706) |
| Net Loss | $(3,136,953) | $(1,562,415) |
| Cash and Cash Equivalents | $19,105,345 | $6,765,954 (Year-end 2004) |
| Total Assets | $25,880,146 | $29,040,721 (Sep 30, 2005) |
| Accumulated Deficit | $(12,616,063) | $(9,479,110) (Sep 30, 2005) |
| Net Cash Used in Operating Activities | $(3,188,513) | $(1,946,017) |
Debt and Liquidity: The company has no long-term debt. Current liabilities totaled $1,456,502 as of December 31, 2005. The company maintains significant liquidity with over $19 million in cash, sufficient to fund operations beyond the end of fiscal year 2006.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 95% to $252,500, driven by a $150,000 development fee from Benitec (Calando subsidiary) and a $65,000 SBIR grant (Aonex subsidiary).
- Expense Surge: Operating expenses more than doubled to $4.3 million. Key drivers included:
- R&D Expenses: Increased 166% to $1.72 million, largely due to Insert Therapeutics expensing ~$900,000 in drug supplies for clinical trials and increased sponsored research at Duke and Stanford.
- Salaries: Increased 176% to $1.37 million due to hiring for Sarbanes-Oxley compliance, investor relations, and technical staff.
- Stock-Based Compensation: Increased 733% to $275,000 following the retrospective adoption of SFAS 123R.
- Discontinued Operations: Nanotechnica, Inc. was dissolved in June 2005; losses are now reported as discontinued operations.
Guidance, Outlook, and Risks
Outlook: Management does not expect product sales revenue in fiscal year 2006. Losses are expected to increase as subsidiaries (Insert, Calando, Aonex) advance development and clinical trials. The company relies on equity financing, grants, and collaborations to fund operations.
Recent Capital Raise: Subsequent to the reporting period (January 24, 2006), the company completed a private placement raising approximately $19.6 million from York Capital Management and Knott Partners.
Key Risks and Contingencies:
- Capital Commitments: As of filing, the company had a remaining commitment to provide $1 million to Aonex Technologies upon meeting milestones. The $2 million commitment to Calando was fulfilled in February 2006.
- Development Risk: Success of nanotechnology commercialization is uncertain and may take a long time.
- Regulatory Risk: Insert Therapeutics submitted an IND application for its first drug candidate (IT-101) in February 2006; Phase I trials are pending FDA approval.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $19.1 million cash balance against the quarterly operating cash burn of ~$3.2 million.
- Capital Commitments: Confirm the status of the $1 million milestone-based funding commitment to Aonex Technologies.
- Stock Dilution: Review the impact of the subsequent $19.6 million private placement and outstanding options (4.21 million options outstanding as of Dec 31, 2005).
- Revenue Quality: Note that revenue is currently non-recurring (grants and one-time development fees) rather than product sales.
- Regulatory Milestones: Monitor the FDA review status of Insert Therapeutics' IND application for IT-101.